SARM1 and neoplasm: Together, these findings demonstrate that inhibition of the SARM1 pathway significantly slowed tumour progression to densely cellular, angiogenic and immune-suppressive lesions, as well as the accompanying transition of tumour cells to MES-like/injured states25,46; instead, it led to the development of more diffuse and less inflamed tumours that more closely mirrored normal neurodevelopmental lineages.